BioNTech SE buys a German production plant with a production capacity of 750 million doses consistent with the year of its Covid-19 vaccine, more than double the amount the company can produce while preparing for the global with its unproven vaccine.
The acquisition of the site from Swiss pharmaceutical giant Novartis AG shows German biotechnology’s confidence in the experimental vaccine to be presented in collaboration with US wife Pfizer Inc. and the Chinese organization Shanghai Fosun Pharmaceutical Group Co. The site will allow BioNTech to build increase production faster than if it had depended on the expansion of existing sites, as planned, CHIEF Ugur Sahin said in an interview Wednesday night.
“Especially in the first part of 2021, we can get more doses than expected,” Sahin said.
BioNTech’s vaccine candidate and rivals are making their way through clinical studies amid intense public scrutiny, and in some countries, political promises. In the United States, Paul Mango, one of the leaders of the administration’s Covid-19 vaccination program, said Wednesday that each and every American can be vaccinated by the end of March.
BioNTech and Pfizer will send a hundred million doses of vaccine this year, enough for another 50 million people to get a two-dose vaccine, and with this source already distributed among several governments, it would not be enough to dominate the United States. Sahin said. Partners expect to download initial knowledge of a 44,000-person exam next month to show if the vaccine is working.
The increase to complete the production capacity will take some time. The new site will be to manufacture 250 million doses of your vaccine in the first part of next year, and up to 750 million doses consistent with the year once it is completely incompatible with the vaccine. The photographs will be used in the Chinese market and other countries around the world, and Pfizer will also produce the vaccine in the United States and Europe.
Together, Pfizer and BioNTech had first stated that they could manufacture more than 1. 3 billion doses of vaccine by the end of next year. Today’s production agreement will increase its combined capacity by at least three hundred million doses according to the year. . Sahin.
BioNTech said it planned to conclude the agreement for the Marburg site, north of Frankfurt, in the fourth quarter, but revealed the monetary terms.